Srinivasa Reddy Natala

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)

Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 60 citations · Full text

Biochemistry, Available Investigational Inhibitor, Medicine +7

Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors

Andre A. Kiryanov, Srinivasa Reddy Natala, Benjamin Jones et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 18 citations · Full text

Combinatorial Chemistry, Sar Development, Medicinal Chemistry +9

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease

Asma Khan, Robert Johnson, Carrie Wittmer et al. · Brain · 2021 · 15 citations · Full text

Line 61, Immunology, Cell Death +23

Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists

Srinivasa Reddy Natala, Agata Habas, Emily M. Stocking et al. · Bioorganic & Medicinal Chemistry Letters · 2021 · 10 citations · Full text

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

Agata Habas, Srinivasa Reddy Natala, Jon K. Bowden-Verhoek et al. · International Journal of Inflammation · 2022 · 10 citations · Full text